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Abstract
Introduction
There is ongoing research into the development of novel molecular markers that may com-
plement fluid cytology malignant pleural effusion (MPE) diagnosis. In this exploratory pilot
study, we hypothesized that there are distinct differences in the pleural fluid microbiome pro-
file of malignant and non-malignant pleural diseases.
Method
From a prospectively enrolled pleural fluid biorepository, samples of MPE were included.
Non-MPE effusion were included as comparators. 16S rRNA gene V4 region amplicon
sequencing was performed. Exact Sequence Variants (ESVs) were used for diversity analy-
ses. The Shannon and Richness indices of alpha diversity and UniFrac beta diversity mea-
sures were tested for significance using permutational multivariate analysis of variance.
Analyses of Composition of Microbiome was used to identify differentially abundant bacterial
ESVs between the groups controlled for multiple hypothesis testing.
Results
38 patients with MPE and 9 with non-MPE were included. A subgroup of patients with meta-
static adenocarcinoma histology were identified among MPE group (adenocarcinoma of
lung origin (LA-MPE) = 11, breast origin (BA-MPE) = 11). MPE presented with significantly
greater alpha diversity compared to non-MPE group. Within the MPE group, BA-MPE was
more diverse compared to LA-MPE group. In multivariable analysis, ESVs belonging to fam-
ily S24-7 and genera Allobaculum, Stenotrophomonas, and Epulopiscium were significantly
enriched in the malignant group compared to the non-malignant group.
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Conclusion
Our results are the first to demonstrate a microbiome signature according to MPE and non-
MPE. The role of microbiome in pleural effusion pathogenesis needs further exploration.
Introduction
Up to 55% of large pleural effusions are malignant pleural effusions (MPE). [1, 2] A majority
of these effusions are secondary to metastatic involvement of the pleura from lung cancer and
breast cancer. [2–4] However, at a fundamental level, our knowledge for the molecular patho-
genesis of initiation and progression of MPE remains poor. There is ongoing research into the
development of novel molecular markers that may complement fluid cytology in the diagnosis
of malignant pleural effusion (MPE). [1] Conventional pleural fluid cytology on first thora-
centesis are positive in only 50% of cases. [2] When the diagnosis is not obtained, repeat thora-
centesis and cytological examination merely confers a small additive diagnostic value and
more invasive procedures such as thoracoscopic pleural biopsy are required. [3, 4]
Investigations have identified associations between specific microbes and different cancers.
The mechanisms by which microbiota modulate carcinogenesis in the lungs, the most adjacent
organ to the pleura, is studied in different lung diseases, including lung cancer [5] Pulmonary
Mycobacterium tuberculosis infection is associated with an increased risk of lung cancer, even
among the never-smokers in a meta-analysis of 30 studies, where the pooled relative risk for
association between TB and lung cancer was 1.76 (95% CI: 1.49, 2.08). [6] Periodontal disease
has also been associated with lung cancer, suggesting an association between the oral micro-
biome and lung cancer risk. [7] The translocation of microbial pathogens leads to a series of
immune responses, which promote carcinogenesis of host cells. [8–11] The estimated trillions
of microbes that inhabit the human body establish a beneficial relationship with the host, but it
is clear that disruption of this homeostasis (dysbiosis) may result in host disease, including
inflammatory disorders and cancers. [12] However, whether there is a specific microbiome
associated with MPE formation has not yet been determined.
In this study, we hypothesized that there are distinct differences in the pleural fluid micro-
biome profile of MPE and non-MPE. In addition, we hypothesized that differences exist
among microbiome profile of cancers of different origin. The primary objective of this study
was to define discriminating features of the pleural fluid microbiome in malignant and non-
malignant pleural effusion. The secondary objective was to compare the microbiome profile
associated with metastatic adenocarcinoma of lung cancer origin to metastatic adenocarci-
noma of breast cancer origin, in the pleural fluid.
Methods
Design and setting
In this exploratory pilot study, from a prospectively enrolled pleural fluid biorepository, pleu-
ral fluid specimens of adult patients (> 18 years of age) were included. Written informed con-
sent was obtained from all patients prior to enrollment in the study. The study was approved
by the local Institutional Review Board. (IRB # HM14281).
Inclusion and exclusion criteria
Adult patients (> 18 years of age) with pleural effusion referred for diagnostic and therapeutic
thoracentesis were recruited from September 2012- December 2013. Study group included
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patients with diagnosis of MPE proven on cytology or pleural biopsy. Non-malignant effusion
were included as comparators in the control group. Non-malignant effusion was defined as an
effusion with negative cytology or pleural biopsy and no evidence of malignancy on 2-year fol-
low up. Patients were excluded if a concomitant second malignancy was present or suspected.
Data and sample collection
Thoracentesis was performed using sterile standard technique (Details of the aspiration proce-
dure are listed under S1 File). Pleural fluid specimens were collected in sterile fashion and
were placed in study test tubes containing 0.1 cc of DNA stabilizing solution. Samples were
stored in a secure freezer at—80˚C. Once recruitment was completed, specimens were thawed
for analysis as described below. Additional recorded parameters were age, sex, race, smoking
status, Eastern Cooperative Oncology Group (ECOG) performance status, medical history and
chest imaging. All data were stored in a de-identified secure database (REDCap). Specimen
processing was performed by laboratory personnel (AS, NG) blinded to the specimens’ origin.
16S rRNA gene amplicon library preparation and sequencing
Following DNA extraction using mitochondrial blockers from PNA bio at 2uM per reaction,
the V4 region of the 16S rRNA gene (515F-806R) was amplified with region-specific primers
that included the Illumina flowcell adapter sequences and a 12-base barcode sequence
(Thompson et al., 2017). [13] Each 25μl PCR reaction contained the following mixture: 12μl of
MoBio PCR Water (Certified DNA-Free; MoBio, Carlsbad, USA), 10μl of 5-Prime HotMaster-
Mix (1×), 1μl of forward primer (5μM concentration, 200pM final), 1μl of Golay Barcode
Tagged Reverse Primer (5μM concentration, 200pM final), and 1μl of template DNA (Thomp-
son et al., 2017). The conditions for PCR were as follows: 94˚C for 3min to denature the DNA,
with 35 cycles at 94˚C for 45s, 50˚C for 60s, and 72˚C for 90s, with a final extension of 10min
at 72˚C to ensure complete amplification. [14] Amplicons were quantified using PicoGreen
(Invitrogen) assays and a plate reader, followed by clean up using UltraClean1 PCR Clean-
Up Kit (MoBio, Carlsbad, USA) and then quantification using Qubit readings (Invitrogen,
Grand Island, USA). The 16S gene amplified samples were sequenced on an Illumina MiSeq
platform at Argonne National Laboratory core sequencing facility according to EMP standard
protocols (http://www.earthmicrobiome.org/emp-standard-protocols/its/). [14]
Internal validity and reagent control
While contamination remains an issue in microbiome studies, we used total of 30 negative
controls to identify DNA extraction kit associated contaminants. Ten wells with the sequenc-
ing reagents of PCR mix (mentioned above) that were used for processing of experimental
specimens were sequenced but without template DNA. The sequencing of the ten reagent con-
trol samples generated less than 500 reads per sample (less than 1ng/ul DNA in each well). The
dominant sequences in the experimental data had higher mean relative abundances among
samples than among non-template controls. This suggests that there was no detectable reagent
contamination that could be attributed to the sample processing. The 6 taxa (exact sequence
variants (ESVs); <0.1% relative abundance) that were annotated in these ten controls are tabu-
lated in S1 Table. In addition to these, 20 blank controls were also sequenced (only microbial
DNA-free water without reagents and template DNA) which failed sequencing due to no
detectable DNA, suggesting no attributable contamination from the water used in the PCR
mix.
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Data processing and statistical analyses
For 16S rRNA gene based analysis, around 2.5 million paired-end reads generated using Illu-
mina MiSeq were joined using join_paired_ends.py script followed by quality-filtering and
demultiplexing using split_libraries_fastq.py script in QIIME 1.9.1. [15] The final set of demulti-
plexed sequences were then selected for sub-OTU picking using DeBlur pipeline. [16] Taxon-
omy was assigned by mapping the ESV sequences against the Greengenes reference database
(http://greengenes.secondgenome.com/?prefix=downloads/greengenes_database/gg_13_5/)
using assign_taxonomy.py script in the QIIME package. In the pipeline, de novo chimeras were
analyzed, artifacts were removed, and Exact Sequence Variants (ESVs) with under 10 reads
were removed using Phyloseq (version-1.26.1) package. [17] The final BIOM file comprised of
2,158 ESVs in 47 samples and average of 7,484 reads per sample was then used for the analyses.
Analyses of patient-level characteristics utilized Pearson χ2 test for categorical data and
one-way ANOVA for continuous variables. Non-metric multidimensional scaling (NMDS)
plots were employed to reveal beta diversity variations based on weighted and unweighted
UniFrac dissimilarity matrices () in Phyloseq (version- 1.26.1) package. [18] Richness, Shan-
non and Simpson indices were used to estimate alpha diversity and the variation between
groups (beta diversity) was statistically tested using paired t-tests and permutational multivari-
ate analysis of variance (PERMANOVA), respectively. Analyses of Composition of Micro-
biome (ANCOM- version 2) [19] was used to identify differentially abundant bacterial ESVs
between the groups at P-value cut-off of 0.05 and Benjamini-Hochberg FDR correction was
implemented. Generalized linear models (GLMs) were run in order to test for correlations
between selected genera (differentially abundant between groups of interest) and the clinical
variables. GLMs were implemented in glm() package (version-1.2.1) using the counts data for
the genera using Poisson regression and “log” link without making assumptions about the data
distribution. The significance of each correlation for the clinical parameters was evaluated
using ANOVA to compare nested models using “chisq” test. For the linear models, standard-
ized beta coefficients were plotted to overcome the bias introduced due to varying scales
(units) for the clinical parameters. [20] GLMs were used to quantify the effect (i.e. the direction
of correlation and the strength of correlation) of the confounding variables i.e. the clinical vari-
ables on microbiome, whereas, ANCOM was used to identify the differentially abundant can-
didates after adjusting for these confounding variables.
In order to track potential sources/contamination from skin and oral cavity in the pleural
microbiome, we employed Bayesian approach using software SourceTracker. [21] We used
publicly available data from the National Institutes of Health Human Microbiome Project
(HMP) for the sample types buccal mucosa, hard palate, saliva, throat, and tongue dorsum as
representatives for the potential contamination from oral cavity and right and left antecubital
fossa as representative of skin associated sources. [22] For this analysis, the pleural samples
were treated as “sink” which were collapsed into one group i.e. pleural microbiome as well as
samples split into two different origin (breast and lung) pleural adenocarcinoma and non-
malignant groups for plotting in R script (version- 3.5.1). [23]
Results
Population and sampling
Pleural fluid specimens were collected from 38 patients with MPE (study group) and 9 patients
with non-MPE (control group). Among the study group, a subgroup of patients with meta-
static adenocarcinoma of the pleura were identified (n = 22, adenocarcinoma of lung cancer
origin (LA-MPE) = 11, adenocarcinoma of breast cancer origin (BA-MPE) = 11).
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The mean (SD) age for the entire cohort was 60 (±8) years and 43% of patients were male.
At the time of specimen collection, the 49% of patients were prior smokers, while 40% were
never smokers and 11% were current smokers. Most patients had an ECOG performance sta-
tus of 1–3. Mean (SD) BMI was 25 (0.9). None of the patients had clinical or radiographic evi-
dence of bronchopleural fistula at the time of fluid collection. Patient characteristics by group
are shown in Table 1.
Pleural microbiota composition and comparison
There were significant differences in microbial alpha diversity indices between malignant and
non-malignant effusions with significantly greater microbial diversity within the malignant
group when compared to the non-malignant group based on Richness and Shannon indices.
(Fig 1A). Within the MPE group, BA-MPE group had significantly greater microbial diversity
compared to the non-malignant group (Fig 1B) based on Shannon and richness indices. Addi-
tionally, the BA-MPE group had significantly (p< 0.05; paired t-test) greater alpha diversity
when compared with the LA-MPE group based on richness and Shannon indices (Fig 1A).
Further, using linear regression and ANOVA test, we identified no statistically significant cor-
relation (p = 0.07) between alpha diversity and potentially confounding variables i.e. age, BMI,
smoking status, and ECOG performance. Using the NMDS plots, no distinct clustering was
noted between the groups based on the beta diversity (for both weighted and unweighted
Table 1. Patients characteristics.
Variables Malignant (38) Non-Malignant (9)
Age (mean) (SD) 61 (1.9) 57 (5.0)
Sex
Males 14 (37%) 6 (67%)
Females 24 (63%) 3 (33%)
BMI (mean)(SD) 25 (0.9) 26 (1.5)
Smoking Status
Former 17 (45%) 6 (67%)
Never 16 (42%) 3 (33%)
Current 5 (13%) 0 (0%)
ECOG
0 2 (5%) 1 (11%)
1 9 (24%) 1 (11%)
2 10 (26%) 5 (56%)
3 10 (26%) 1 (11%)
4 4 (11%) 0 (0%)
Not assessed 3 (8%) 1 (11%)
Etiology
Lung Adeno. 11 (29%) CHF 4 (44%)
Lung other 3 (8%) Renal 2 (22%)
Breast Adeno 11 (29%) HH 3 (33%)
Colon Adeno. 3 (8%)
Lymphoma 4 (10%)
Other 6 (16%)
SD: Standard deviation, ECOG: Eastern Cooperative Oncology Group, BMI: Body mass index, Adeno:
Adenocarcinoma, HH: Hepatic Hydrothorax, CHF: congestive heart failure, SLE: Systemic Lupus Erythematosus.
https://doi.org/10.1371/journal.pone.0232181.t001
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UniFrac distance matrices) (S1 Fig in S1 File). The PERMANOVA testing generated a non-sig-
nificant p-value for the multi-group comparison based on beta diversity metrics (p>0.05;
PERMANOVA).
Using ANCOM2 and adjusting for age, BMI, smoking status and ECOG performance sta-
tus, we identified 5 ESVs that could differentiate between the MPE and non-MPE groups.
ESV1 annotated to the Acinetobacter, and was enriched in the non-malignant group. ESVs
belonging to family S24-7 and genera Allobaculum, Stenotrophomonas, and Epulopiscium were
significantly enriched in the malignant group compared to the non-malignant group (Fig 2A).
We identified 4 ESVs including those annotated to family S24-7, order Clostridiales, genus
Allobaculum and genus Acinetobacter (ESV2) that were significantly enriched in the BA-MPE
group compared to non-malignant group, while ESV1 was still significantly enriched in the
non-malignant group (Fig 2B). A 3rd Acinetobacter ESV (ESV3) was significantly enriched in
the non-malignant group compared to the LA-MPE group (Fig 2C). Interestingly, S24-7 ESV
Fig 1. (A) Boxplots showing distribution of Richness, Shannon and Simpson alpha diversity indices between the all malignant effusions and all non-malignant effusion.
(B) Boxplots showing distribution of Richness, Shannon and Simpson alpha diversity indices between the breast adenocarcinoma (BA-MPE), lung adenocarcinoma
(LA-MPE), non-malignant and rest of the malignant groups. The � and �� represent p-values of� 0.05 and p-value� 0.01 respectively determined using paired t-test.
https://doi.org/10.1371/journal.pone.0232181.g001
PLOS ONE Malignant pleural effusion microbiome
PLOS ONE | https://doi.org/10.1371/journal.pone.0232181 May 8, 2020 6 / 13
enriched in BA-MPE was also significantly enriched in LA-MPE compared to the non-malig-
nant group (Fig 2B and 2C). An ESV annotated as genus Actinobacillus was significantly
enriched in LA-MPE compared to BA-MPE (Fig 2D).
In order to further elucidate relationships and potential underlying confounders, GLMs
were run for the BA-MPE and LA-MPE microbiome (S2 Fig in S1 File). GLMs were used to
evaluate any correlation (at 95% CI) between differential abundance patterns of select taxa and
variables of age, gender, body mass index (BMI), smoking status and ECOG performance
status.
Furthermore, the pleural fluid taxonomic composition in all MPE, LA-MPE, BA-MPE and
non-malignant effusions are displayed. Only taxa greater than 1% relative abundance are plot-
ted in Fig 3.
Tracking the sources of potential contamination
Source tracking was used to identify the potential origin/sources of the bacterial ESVs enriched
in the pleural microbiome. As no prior pleural microbiome reference dataset was available, we
used data from the Human Microbiome Project to represent the oral cavity (buccal mucosa,
Fig 2. Analyses of Composition of Microbiome (ANCOM) to identify statistically significant Exact Sequence Variants (ESVs) between (A) malignant and non-malignant,
(B) lung adenocarcinoma (LA-MPE) and non-malignant group, (C) LA-MPE and BA-MPE, and (D) breast adenocarcinoma (BA-MPE) and non-malignant group. The p-
values corrected using Benjamini-Hochberg FDR correction (i.e. q-values) are presented. X-axis shows relative abundance. ANCOM calculations were adjusted for age,
BMI, ECOG performance status and smoking status.
https://doi.org/10.1371/journal.pone.0232181.g002
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hard palate, saliva, throat, and tongue dorsum) and skin (right and left antecubital fossa) tis-
sue-associated microbiota. These data were used as tissue surrogates for potential sources of
contamination from the oral cavity or skin that could occur during pleural resection. These
analyses demonstrated a very low contribution (~0.1%) from skin and oral cavity microbiota
towards the composition of pleural microbiome, which suggests very low contamination
(Fig 4).
Discussion
These results suggest that there may be a distinct microbial profile in MPE when compared to
non-malignant effusions. The variations noted between two different cancer cell origins fur-
ther suggest that these differences are associated with the tissue subtype driving MPE.
A dysbiotic microbiota may facilitate carcinogenesis through a variety of mechanisms that
have been reported in the literature. [13, 24–26] Microbiota are thought to promote carcino-
genesis through the release of genotoxins that could result in host-cell DNA damage. [13,24]
Bacterial toxins are also thought to promote chronic inflammation triggering damage to host
cells. [25] Our preliminary data suggests that not only are there different microbial consortia
Fig 3. Distribution of all taxa (that are greater than 1% abundant) in the pleural fluid in malignant and non-malignant groups (A) and in BA-MPE and LA-MPE groups.
https://doi.org/10.1371/journal.pone.0232181.g003
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present in non-malignant and malignant pleural effusion, but importantly there is a distinctive
association between different cancer cell origins with a specific microbiome signature. These
differences provide valuable biomarkers to improve cell origin prediction, and provide targets
to aid in the identification of the contribution of the microbiome to non-malignant and malig-
nant effusion development.
Our analysis in a cohort of pleural effusion specimens from patients with cytology and/or
histology proven malignant effusion provided a significantly greater microbial diversity than
non-malignant effusions. Additionally, 5 different ESVs were identified that could differentiate
between the two groups. Some of these ESVs have been correlated to carcinogenesis in other
organs. Wei et al. found an increase in Ruminococcus obeum and Allobaculum-like bacteria in
the feces of rats developing precancerous mucosal lesions. [27] Another study reported that
Fig 4. Source tracker analyses results- we used publicly available data from the Human Microbiome Project to identify potential sources (or contamination) of
bacterial ESVs enriched in the pleural microbiome. 16S rRNA gene sequencing data from buccal mucosa, hard palate, saliva, throat, and tongue dorsum were used as
potential sources for the oral cavity and right and left antecubital fossa as representative of skin associated sources. Here (A) we report the relative proportion distribution
of each of the sources in the Pleural microbiome of the total study population (38) as well pleural microbiome data displayed in group-wise fashion. A magnified view of
the contribution of each HMP source in each group, is depicted (B).
https://doi.org/10.1371/journal.pone.0232181.g004
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Stenotrophomonas maltophilia colonization/infection may be associated with a significant
increase in cancer rates over the past two decades. [28] None of the aforementioned studies
have shown a relationship between these taxa and pleural malignancy, but their association in
other malignancies and models of carcinogenesis is noteworthy.
Cancer of another serous cavity, the peritoneum, and its relationship to microbiome of the
peritoneal fluid shows that numerous bacterial taxa are consistently present in patients with
pseudomyxoma peritonei. [29] This relation is thought to be secondary to inflammation and
translocation of microbial organisms into the peritoneal cavity. We hypothesized that the pres-
ence of such inflammatory responses in the pleura and adjacent organisms such as the lung
and the diaphragm, could result in microbial translocation in to the pleural space with effects
on MPE development.
To assess the overall role of resident airways and oral cavity microbiota, we used oral cavity
specimen surrogates from the HMP dataset. Additionally, assuming for possible skin contami-
nation during thoracentesis, we used skin tissue surrogates. Based on our analyses, skin and
oral cavity microbiota contribution to pleural microbiome was estimated at approximately 1%
only. Other potential sources of direct lung/airway contamination due to pleural injury as a
result of alveolar-pleural fistula (APF) and bronchopleural fistula (BPF) were excluded. Hence,
majority of the pleural fluid microbiome source identified in our study remains unknown. The
results of this study imply the microbiota differs in patients with MPE compared to patients
with non-MPE, even after adjusting for age, gender, BMI, smoking status and ECOG perfor-
mance score.
A small sample size is the main limitation of the present study. This is primarily due to the
exploratory nature of microbiome profile investigation in the pleural space which has not been
done before. This data aid in power and effect size calculation and the formulation of larger
follow-up studies to investigate the role of microbiome as a classifier and its potential associa-
tion with different pleural disease states. Another limitation is disease heterogeneity in both
groups. For this reason, we selected the largest homogeneous groups for additional analyses
(LA-MPE and BA-MPE). Analyses were performed within and between groups, to assess both
microbial diversity, as well as detect differentiating ESVs. Additionally, multivariable analyses,
were performed separately in BA-MPE and LA-MPE groups. Although adjustments were per-
formed to account for numerous potential confounders, other unmeasured confounders could
influence the effect estimates and should be included in larger future studies. One of the limita-
tions of microbiome analysis is the possibility of contamination during tissue acquisition. To
prevent pleural space contamination during the procedure, all procedures are performed using
standard sterile technique. Surface sterilization using standard technique however does not
completely prevent the contamination of microbiome. Organisms such as Myroides, William-
sia, Brevundimonas, are known to be on surfaces, water, and commonly found in background.
[30, 31]
As an alternate method of source detection and contamination, the HMP data was used.
The HMP includes microbial communities from 300 healthy individuals from 5 centers, across
several different sites on the human body including the oral cavity and skin. [11] However, the
healthy microbial communities in HMP, may not be an accurate representation of oral cavity
and skin microbiome in a diseased state. In fact, ESVs belonging to family S24-7 have been
associated with airway microbiome in Urethane-induced pulmonary adenocarcinoma in mice
[32], While Stenotrophomonas and Acinetobacter have been associated with bronchiectasis and
COPD, respectively. [33, 34]
Finally, the taxonomic composition of the pleural fluid has not been investigated before,
hence our lack of knowledge of the pleural space microbiome make-up in a healthy thoracic
cavity, prevents a true comparison of MPE with “normal” pleural fluid.
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The contribution of microbiome to benign and malignant effusion development should be
further investigated. Whether a dysbiotic relationship leads to cancer genesis or, the presence
of distinctive microbiome profile, is the result but not the cause of the developing cancer in
MPE is unknown. Exploration of the above differences may help expose the underlying molec-
ular mechanisms that drive initiation and progression of malignant pleural effusion and
unmask the carcinogenesis process that leads to cancer.
In conclusion, our results link a distinctive association between different cancer cell origins
with microbiome and identify different microbial compositions present in non-malignant and
malignant pleural effusion. The results of this study should be confirmed in larger prospective
studies in homogeneous populations and should include specimens from other potential sur-
faces and sources of contamination. “Can we manipulate microbial communities to improve
clinical outcomes of pleural diseases?” is an intriguing and inevitable question and needs
future exploration.
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